Research statistics

CJC-1295 research: publications and trials

What has been published on CJC-1295: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether CJC-1295 works or is safe. For what it is and what the studies found, see the CJC-1295 profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

27

Since 2005

Publications in 2026 so far

6

Through November 15, 2026

Human clinical research

11.1%

3 of 27 classified

Registered clinical trials

1

ClinicalTrials.gov

Randomized controlled trials

1

Publications reporting an RCT in people

Systematic reviews and meta-analyses

0

Preclinical studies

59.3%

7 animal · 9 in vitro · 0 computational

Records that only mention it

8

Not counted above

Status in the library: Research only. Groups: Growth hormone axis.

What to keep in mind

  • Fewer than three randomized controlled trials are indexed.

Publications by year

CJC-1295 publications by year and evidence

2005, Human clinical research: 1 of 22005, Preclinical (animal, in vitro, computational): 1 of 22006, Human clinical research: 1 of 22006, Preclinical (animal, in vitro, computational): 1 of 22009, Human clinical research: 1 of 22009, Preclinical (animal, in vitro, computational): 1 of 22010, Preclinical (animal, in vitro, computational): 1 of 12011, Reviews and meta-analyses: 1 of 12013, Preclinical (animal, in vitro, computational): 1 of 12015, Preclinical (animal, in vitro, computational): 1 of 12016, Preclinical (animal, in vitro, computational): 1 of 22016, Reviews and meta-analyses: 1 of 22018, Preclinical (animal, in vitro, computational): 1 of 12019, Preclinical (animal, in vitro, computational): 1 of 12020, Preclinical (animal, in vitro, computational): 1 of 12021, Preclinical (animal, in vitro, computational): 1 of 12022, Preclinical (animal, in vitro, computational): 2 of 22023, Preclinical (animal, in vitro, computational): 1 of 12024, Preclinical (animal, in vitro, computational): 1 of 12025, Other and not yet classified: 1 of 12026 (to date), Preclinical (animal, in vitro, computational): 1 of 62026 (to date), Reviews and meta-analyses: 5 of 6Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified024620052011201820222026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
200511002
200611002
200911002
201001001
201100101
201301001
201501001
201601102
201801001
201901001
202001001
202101001
202202002
202301001
202401001
202500011
2026 (to date)01506

Study types

In vitro study9
Animal study7
Review7
Other clinical trial2
Editorial, letter or other1
Randomized controlled trial1

Research areas

From MeSH major topics. A paper can be in several areas.

Endocrinology10
Metabolic health5
Longevity and aging4
Tissue repair4
Musculoskeletal3
Neurological and mental health3
Cardiovascular1
Dermatology1
Immune system1
Obesity and weight management1
Reproductive and sexual health1

Registered clinical trials

A registration is not a result.

Terminated: 1
Phase 2: 1

TrialStatusPhaseStartedResults
A Study to Evaluate CJC 1295 in HIV Patients With Visceral ObesityNCT00267527 · 120 enrolledTerminatedPhase 22005-12—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

    The Journal of clinical endocrinology and metabolism · December 13, 2005 · Randomized controlled trial · cited 48 times

    PMID 16352683 · DOI 10.1210/jc.2005-1536 · Human clinical research

  2. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · April 21, 2009 · Other clinical trial · cited 28 times · open access

    PMID 19386527 · DOI 10.1016/j.ghir.2009.03.001 · Human clinical research

  3. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

    The Journal of clinical endocrinology and metabolism · October 3, 2006 · Other clinical trial · cited 36 times

    PMID 17018654 · DOI 10.1210/jc.2006-1702 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.

    Methods (San Diego, Calif.) · August 18, 2011 · Review · cited 99 times

    PMID 21871962 · DOI 10.1016/j.ymeth.2011.08.009 · Reviews and meta-analyses

  2. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.

    Drug testing and analysis · November 1, 2010 · In vitro study · cited 59 times

    PMID 21204297 · DOI 10.1002/dta.233 · In vitro studies

  3. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

    The Journal of clinical endocrinology and metabolism · December 13, 2005 · Randomized controlled trial · cited 48 times

    PMID 16352683 · DOI 10.1210/jc.2005-1536 · Human clinical research

  4. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.

    Analytical and bioanalytical chemistry · February 15, 2016 · In vitro study · cited 43 times · open access

    PMID 26879649 · DOI 10.1007/s00216-016-9377-3 · In vitro studies

  5. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.

    Substance use & misuse · January 15, 2016 · Review · cited 41 times · open access

    PMID 26771670 · DOI 10.3109/10826084.2015.1082595 · Reviews and meta-analyses

Latest publications

  1. Detection of CJC-1295 in Equine Plasma by ELISA.

    Drug testing and analysis · October 14, 2026 · Animal study · cited 0 times · open access

    PMID 42876013 · DOI 10.1002/dta.70171 · Animal studies

  2. Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

    The American journal of sports medicine · August 11, 2026 · Review · cited 1 times · open access

    PMID 42578445 · DOI 10.1177/03635465261464420 · Reviews and meta-analyses

  3. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

    Frontiers in endocrinology · June 18, 2026 · Review · cited 1 times · open access

    PMID 42395176 · DOI 10.3389/fendo.2026.1822475 · Reviews and meta-analyses

  4. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    Sports medicine (Auckland, N.Z.) · April 12, 2026 · Review · cited 8 times · open access

    PMID 41966639 · DOI 10.1007/s40279-026-02437-0 · Reviews and meta-analyses

  5. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

    Frontiers in aging · April 7, 2026 · Review · cited 4 times · open access

    PMID 42021992 · DOI 10.3389/fragi.2026.1790247 · Reviews and meta-analyses

  6. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

    The American journal of sports medicine · January 1, 2026 · Review · cited 12 times

    PMID 41476424 · DOI 10.1177/03635465251357593 · Reviews and meta-analyses

  7. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

    Journal of pharmaceutical and biomedical analysis · October 20, 2025 · Editorial, letter or other · cited 1 times

    PMID 41138283 · DOI 10.1016/j.jpba.2025.117207 · Commentary and other

  8. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

    Journal of mass spectrometry : JMS · January 1, 2024 · In vitro study · cited 5 times · open access

    PMID 38197510 · DOI 10.1002/jms.4996 · In vitro studies

  9. Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

    Analytical biochemistry · October 6, 2023 · In vitro study · cited 4 times

    PMID 37806509 · DOI 10.1016/j.ab.2023.115336 · In vitro studies

  10. Probing for peptidic drugs (2-10 kDa) in doping control blood samples.

    Analytical science advances · August 22, 2022 · In vitro study · cited 9 times · open access

    PMID 38716080 · DOI 10.1002/ansa.202200027 · In vitro studies

Browse all 27 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: CJC-1295; cjc-1295-dac; CJC-1295 with DAC; DAC:GRF; Modified GRF with DAC

((TITLE_ABS:"CJC-1295" OR CHEM:"CJC-1295" OR TITLE_ABS:"CJC1295" OR CHEM:"CJC1295") OR (TITLE_ABS:"cjc-1295-dac" OR CHEM:"cjc-1295-dac" OR TITLE_ABS:"cjc1295-dac" OR CHEM:"cjc1295-dac") OR (TITLE_ABS:"CJC-1295 with DAC" OR CHEM:"CJC-1295 with DAC" OR TITLE_ABS:"CJC1295 with DAC" OR CHEM:"CJC1295 with DAC") OR (TITLE_ABS:"DAC:GRF" OR CHEM:"DAC:GRF") OR (TITLE_ABS:"Modified GRF with DAC" OR CHEM:"Modified GRF with DAC")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). CJC-1295 research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/cjc-1295